Skip to main content

and
  1. No Access

    Article

    Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

    Hypoactive BRAF mutants bind more tightly than wild type to the upstream regulator RAS, thus amplifying to amplify ERK signalling; tumours expressing these mutants require coexistent mechanisms for RAS activat...

    Zhan Yao, Rona Yaeger, Vanessa S. Rodrik-Outmezguine, Anthony Tao in Nature (2017)

  2. Article

    Open Access

    Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer

    Protein biomarkers are widely used in cancer diagnosis, prognosis, and prediction of treatment response. Here we introduce the use of targeted multiplex proteomics (TMP) as a tool to simultaneously measure a p...

    Garazi Serna, Fiorella Ruiz-Pace, Fabiola Cecchi, Roberta Fasani in Scientific Reports (2019)

  3. Article

    Open Access

    The addition of FAIMS increases targeted proteomics sensitivity from FFPE tumor biopsies

    Mass spectrometry-based targeted proteomics allows objective protein quantitation of clinical biomarkers from a single section of formalin-fixed, paraffin-embedded (FFPE) tumor tissue biopsies. We combined hig...

    Steve Sweet, David Chain, Wen Yu, Philip Martin, Marlon Rebelatto in Scientific Reports (2022)

  4. Article

    Open Access

    HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer

    Many targeted cancer therapies rely on biomarkers assessed by scoring of immunohistochemically (IHC)-stained tissue, which is subjective, semiquantitative, and does not account for expression heterogeneity. We...

    Ansh Kapil, Andreas Spitzmüller, Nicolas Brieu, Susanne Haneder in Scientific Reports (2024)